﻿<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>BioSpectrum Asia - RSS Feed</title>
    <link>http://biospectrumasia.ciol.com/rss/</link>
    <description>BioSpectrum Asia is a specialized information platform for life science articles in the Asia Pacific that includes life sciences articles, pharma news, life science products reviews and other information</description>
    <language>en-us</language>
    <pubDate>2/8/2010 5:30:05 PM</pubDate>
    <lastBuildDate>2/8/2010 5:30:05 PM</lastBuildDate>
    <docs>http://biospectrumasia.ciol.com/rss/</docs>
    <generator>BSA Feed Generator</generator>
    <managingEditor>sureshn@cybermedia.co.in</managingEditor>
    <webMaster>webmasterciol@cybermedia.co.in</webMaster>
    <item>
      <title>Waters introduces Acquity UPLC H-Class System</title>
      <link>http://www.biospectrumasia.com/content/080210OTH12010.asp</link>
      <description>According to the company, the new H-Class system is designed to replace High Performance Liquid Chromatography (HPLC) systems and accelerate Ultra Performance Liquid Chromatography (UPLC) adoption among HPLC users</description>
      <pubDate>2/8/2010 5:15:34 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210OTH12010.asp</guid>
    </item>
    <item>
      <title>Australia announces GM canola trial results</title>
      <link>http://www.biospectrumasia.com/content/080210AUS12009.asp</link>
      <description>The Australian Grains Research and Development Corporation (GRDC), supported by the National Variety Trials (NVT), has released the results of 150 canola trials conducted across the country in 2009</description>
      <pubDate>2/8/2010 3:13:28 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210AUS12009.asp</guid>
    </item>
    <item>
      <title>Lupin bags FDA approval for hypertension capsules</title>
      <link>http://www.biospectrumasia.com/content/080210IND12008.asp</link>
      <description>The capsules, Amlodipine/Benazepril, are the AB-rated generic equivalent of Novartis'' Lotrel capsules indicated for the treatment of hypertension</description>
      <pubDate>2/8/2010 2:56:01 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210IND12008.asp</guid>
    </item>
    <item>
      <title>ClinTec''s sales revenue up by 45%</title>
      <link>http://www.biospectrumasia.com/content/080210IND12007.asp</link>
      <description>The full service contract research organisation has also expanded its client base and signed new contracts with 11 of the world''s top 25 pharmaceutical firms</description>
      <pubDate>2/8/2010 2:20:42 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210IND12007.asp</guid>
    </item>
    <item>
      <title>Venus Remedies receives GMP certification from Ethiopia</title>
      <link>http://www.biospectrumasia.com/content/080210IND12006.asp</link>
      <description>Indian pharma company, Venus Remedies has received yet another GMP approval from Ethiopias Drug Administration and Control Authority (DACA) for four of its facilities</description>
      <pubDate>2/8/2010 2:15:10 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210IND12006.asp</guid>
    </item>
    <item>
      <title>GSK Japan gets new President</title>
      <link>http://www.biospectrumasia.com/content/080210JPN12005.asp</link>
      <description>GlaxoSmithKline has appointed Mr Philippe Fauchet as the President of GSK Japan. Mr Fauchet joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development</description>
      <pubDate>2/8/2010 12:34:17 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210JPN12005.asp</guid>
    </item>
    <item>
      <title>Daiichi initiates phase III trial of thromboembolism drug</title>
      <link>http://www.biospectrumasia.com/content/080210JPN12004.asp</link>
      <description>Daiichi Sankyo has initiated a large-scale pivotal phase III trial for edoxaban, its investigational oral factor Xa inhibitor. This new study is evaluating the safety and efficacy of edoxaban in reducing venous thromboembolic complications</description>
      <pubDate>2/8/2010 12:17:34 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210JPN12004.asp</guid>
    </item>
    <item>
      <title>Korean firm completes hypertension drug trial</title>
      <link>http://www.biospectrumasia.com/content/080210KOR12003.asp</link>
      <description>Boryung Pharmaceutical, one of South Korea''s largest pharmaceutical companies, has completed its final clinical test on a new drug that will help treat patients with high blood pressure</description>
      <pubDate>2/8/2010 11:19:21 AM</pubDate>
      <guid>http://www.biospectrumasia.com/content/080210KOR12003.asp</guid>
    </item>
    <item>
      <title>SIRO Clinpharm to go for IPO by 2011</title>
      <link>http://www.biospectrumasia.com/content/050210IND12002.asp</link>
      <description>The Indian CRO, SIRO Clinpharm has chalked out major plans for North America and South East Asia to achieve a turnover of Rs 500 crore in the coming months. SIRO Clinpharm''s investors will go in for an exit strategy through an IPO route by 2011</description>
      <pubDate>2/5/2010 4:34:13 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210IND12002.asp</guid>
    </item>
    <item>
      <title>Achillion licences Elvucitabine development in China to GCAT</title>
      <link>http://www.biospectrumasia.com/content/050210CHN12001.asp</link>
      <description>Achillion Pharmaceuticals has executed a license agreement for elvucitabine, its nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection with GCA T</description>
      <pubDate>2/5/2010 4:26:19 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210CHN12001.asp</guid>
    </item>
    <item>
      <title>IOLCP''s income up by 27.70%</title>
      <link>http://www.biospectrumasia.com/content/050210IND12000.asp</link>
      <description>IOL Chemicals and Pharmaceuticals Limited (IOLCP), one of the largest producers of APIs, Ibuprofen and specialty chemicals in India, has announced its latest financial results for the quarter ended December 31, 2009</description>
      <pubDate>2/5/2010 4:08:51 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210IND12000.asp</guid>
    </item>
    <item>
      <title>GSK launches specialist unit for rare diseases</title>
      <link>http://www.biospectrumasia.com/content/050210OTH11999.asp</link>
      <description>GSK has formed a new standalone unit specializing in the development and commercialization of medicines for rare diseases</description>
      <pubDate>2/5/2010 2:46:01 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210OTH11999.asp</guid>
    </item>
    <item>
      <title>CBaySystems inks agreement to acquire Spheris</title>
      <link>http://www.biospectrumasia.com/content/050210OTH11998.asp</link>
      <description>CBaySystems Holdings, one of the leading providers of technology-enabled medical transcription and related healthcare revenue cycle solutions, announces that two of its subsidiaries have agreed to purchase Spheris</description>
      <pubDate>2/5/2010 1:25:34 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210OTH11998.asp</guid>
    </item>
    <item>
      <title>Unichem''s facility gets recertification from MHRA</title>
      <link>http://www.biospectrumasia.com/content/050210IND11997.asp</link>
      <description>Unichem Laboratories has received recertification from Medicines and Healthcare Products Regulatory Agencies (MHRA), UK for its Ghaziabad, India, formulation facility. The facility is recertified for medicines for human and veterinary use</description>
      <pubDate>2/5/2010 12:54:53 PM</pubDate>
      <guid>http://www.biospectrumasia.com/content/050210IND11997.asp</guid>
    </item>
  </channel>
</rss>